A new method for rapid screening of minor tranquillizers in mice

Boissier, J R; Simon, Pierre; Aron, C

doi:10.1016/0014-2999(68)90170-2

Cited by 116 publications

(29 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies and our own pilot experiments had revealed that diazepam at 1 mg/kg i.p. produced anxiolytic-like effects devoid of marked locomotor inhibition (Boissier, Simon, & Aron, 1968;Treit & Fundytus, 1988) or suppression of instrumental responding (George, Hutson, & Stephens, 2009). Due to sedative effects of this drug, higher doses reduced basal rates of leverpressing on their own (see also George et al, 2009).…”

Section: Drug Treatmentmentioning

confidence: 99%

The effects of acute stress on Pavlovian-instrumental transfer in rats

Pielock

Braun

Hauber

2012

Cogn Affect Behav Neurosci

View full text Add to dashboard Cite

Pavlovian stimuli invigorate ongoing instrumental action, a phenomenon termed the Pavlovian-instrumental transfer (PIT) effect. Acute stressors can markedly enhance the release of corticotropin-releasing factor (CRF), and CRF injection into the nucleus accumbens increases the PIT effect. However, it is unknown whether acute stressors by themselves would amplify the PIT effect. Here, we examined the effects of acute stressors on PIT. Rats first received Pavlovian and instrumental training, and then the impact of the Pavlovian stimuli on instrumental responding was analyzed in the subsequent PIT test. Acute stressors were applied prior to the PIT test. Because the effects of acute stressors critically depend on stressor type and time of day, we used two acute stressors that involved one or several distinct stressors (denoted here as "single" vs. "multiple" stressors) applied either in the light or the dark period of the light:dark cycle. The results revealed that single and multiple stressors applied in the light period did not alter the PIT effect-that is, the ability of an appetitive Pavlovian stimulus to enhance leverpressing-or the basal leverpress rate. When applied in the dark period, single and multiple stressors also did not alter the PIT effect, but they did markedly reduce the basal leverpress rate. Diazepam pretreatment did not counteract the declines in basal instrumental responding in the PIT test that were induced by either a single or multiple stressors. Our findings suggest that acute stressors were unable to amplify the incentive salience of rewardpredictive Pavlovian stimuli to activate instrumental responding, but, depending on the time of day of stressor exposure, they did reduce basal instrumental responding.

show abstract

Section: Drug Treatmentmentioning

confidence: 99%

The effects of acute stress on Pavlovian-instrumental transfer in rats

Pielock

Braun

Hauber

2012

Cogn Affect Behav Neurosci

View full text Add to dashboard Cite

show abstract

“…The test apparatus is based on the one described by Boissier et al (1968) for mice and adapted to gerbils. The apparatus consists of a cage with a floor composed of four square metal plates connected to a device that can generate electric shocks (1.5 mA; 0.3 s).…”

Section: Models Of Anxietymentioning

confidence: 99%

Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders

Stemmelin

Cohen

Terranova

et al. 2007

Neuropsychopharmacol

109

View full text Add to dashboard Cite

The characterization of the first selective orally active and brain-penetrant b 3 -adrenoceptor agonist, SR58611A (amibegron), has opened new possibilities for exploring the involvement of this receptor in stress-related disorders. By using a battery of tests measuring a wide range of anxiety-related behaviors in rodents, including the mouse defense test battery, the elevated plus-maze, social interaction, stressinduced hyperthermia, four-plate, and punished drinking tests, we demonstrated for the first time that the stimulation of the b 3 receptor by SR58611A resulted in robust anxiolytic-like effects, with minimal active doses ranging from 0.3 to 10 mg/kg p.o., depending on the procedure. These effects paralleled those obtained with the prototypical benzodiazepine anxiolytic diazepam or chlordiazepoxide.Moreover, when SR58611A was tested in acute or chronic models of depression in rodents, such as the forced-swimming and the chronic mild stress tests, it produced antidepressant-like effects, which were comparable in terms of the magnitude of the effects to those of the antidepressant fluoxetine or imipramine. Supporting these behavioral data, SR58611A modified spontaneous sleep parameters in a manner comparable to that observed with fluoxetine. Importantly, SR58611A was devoid of side effects related to cognition (as shown in the Morris water maze and object recognition tasks), motor activity (in the rotarod), alcohol interaction, or physical dependence. Antagonism studies using pharmacological tools targeting a variety of neurotransmitters involved in anxiety and depression and the use of mice lacking the b 3 adrenoceptor suggested that these effects of SR58611A are mediated by b 3 adrenoceptors. Taken as a whole, these findings indicate that the pharmacological stimulation of b 3 adrenoceptors may represent an innovative approach for the treatment of anxiety and depressive disorders.

show abstract

“…The test apparatus is based on that described by Boissier et al (1968). The apparatus consisted of a cage with a floor composed of four rectangular metal plates connected to a device that can generate electric shocks (1 mA, 0.2 s).…”

Section: Light/dark Test In Micementioning

confidence: 99%

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin-Releasing Factor₁ Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders

Griebel

Simiand²,

Steinberg³

et al. 2002

J Pharmacol Exp Ther

232

146

View full text Add to dashboard Cite

The present study investigated the effects of the novel corticotrophin-releasing factor (CRF) 1 receptor antagonist 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A) in a variety of rodent models of anxiety, including conflict procedures (punished drinking and four-plate), exploration models (elevated plus-maze and light/ dark), a fear/anxiety defense test battery, and several procedures based on stress-induced changes in physiological (isolation-induced hyperthermia and tail pinch-induced cortical norepinephrine release) or behavioral (social defeat-induced anxiety, maternal separation-induced vocalization) parameters. Moreover, the effects of SSR125543A were investigated in acute (forced swimming) and chronic (chronic mild stress; CMS) models of depression. SSR125543A and the CRF 1 receptor antagonist antalarmin displayed limited efficacy in exploration-based anxiety models. In contrast, both compounds produced clear-cut anxiolytic-like activity in models involving inescapable stress, including the conflict procedures, the social defeat-induced anxiety paradigm and the defense test battery (3-30 mg/kg i.p. or p.o.). These effects paralleled those of the anxiolytic diazepam. In addition, SSR125543A and antalarmin antagonized stress-induced hyperthermia, distress vocalization, and cortical norepinephrine release. In the forced swimming test, 30 mg/kg p.o. SSR125543A and 3 to 30 mg/kg p.o. antalarmin produced clear antidepressant-like effects. These latter results were strengthened by the findings from the CMS, which showed that repeated administration of 10 mg/kg i.p. SSR125543A for 30 days improved the degradation of the physical state, the reduction of body weight gain, and anxiety produced by stress. Together, these data indicate that SSR125543A shows good activity in acute and chronic tests of unavoidable stress exposure, suggesting that it may have a potential in the treatment of depression and some forms of anxiety disorders.Corticotropin-releasing factor (CRF) has been identified as a neuropeptide that plays a central role in the coordination of neuroendocrine, autonomic, and behavioral responses to stress (Vale et al., 1981). It is the main regulator of basal and stress-induced release of the adrenocorticotropic hormone (ACTH) (Stout et al., 1995). Two CRF receptor subtypes, CRF 1 and CRF 2 , with distinct anatomical localization and pharmacology have been identified (Chalmers et al., 1996). CRF 1 receptor expression is most abundant in neocortical, cerebellar, and limbic structures, whereas CRF 2 receptor expression is generally prominent in subcortical structures. This anatomical information provided a basis for functional hypotheses related to CRF receptor subtypes and suggested that CRF may contribute significantly both to behavioral responses to stress and emotional behavior itself. This idea has been substantiated by numerous studies showing that i.c.v. application of CRF in rod...

show abstract

A new method for rapid screening of minor tranquillizers in mice

Cited by 116 publications

References 6 publications

The effects of acute stress on Pavlovian-instrumental transfer in rats

The effects of acute stress on Pavlovian-instrumental transfer in rats

Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders

Contact Info

Product

Resources

About